Literature DB >> 34018640

Dysregulated circ_0004913, circ_0008160, circ_0000517, and their potential as biomarkers for disease monitoring and prognosis in hepatocellular carcinoma.

Xiaoqian Li1, Jun Yang2, Xuefeng Yang1, Ting Cao1.   

Abstract

OBJECTIVE: Circular RNA_0004913 (circ_0004913), circular RNA_0008160 (circ_0008160), and circular RNA_0000517 (circ_0000517) are shown to be dysregulated in HCC tissues and cell lines, and also show potential in regulating hepatocellular carcinoma (HCC) pathogenesis. This current study attempted to find possible associations of circ_0004913, circ_0008160, and circ_0000517 with clinical features and prognosis of HCC patients.
METHODS: A hundred and fifty HCC patients who received hepatectomy were retrospectively reviewed, and their resected specimens including tumor tissues and paired adjacent tissues were obtained, in which the circ_0004913, circ_0008160, and circ_0000517 expressions were detected. Overall survival (OS) data were collected according to the clinical visit records.
RESULTS: Circ_0004913 (p < 0.001) and circ_0008160 (p < 0.001) were downregulated, while circ_0000517 (p < 0.001) was upregulated in tumor tissue compared with paired adjacent tissue. Additionally, tumor circ_0004913 was negatively associated with largest tumor size (p = 0.009) and Barcelona clinic liver cancer (BCLC) stage (p = 0.020), while tumor circ_0008160 and circ_0000517 were not correlated with any clinicopathological features of HCC patients (all p > 0.05). Tumor circ_0004913 high expression was associated with prolonged OS in total HCC patients (p = 0.008) and in subgroup of patients with largest tumor size <5 cm (p = 0.008). Tumor circ_0008160 high expression was correlated with longer OS in patients with BCLC stage B (p = 0.026). Univariate Cox's analysis disclosed that tumor circ_0004913 high expression was correlated with longer OS; while after adjustment by multivariate Cox's analysis, it failed to predict OS independently.
CONCLUSION: Circ_0004913 was downregulated in tumor tissue and may serve as a biomarker for evaluating disease severity and prognosis in HCC patients.
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Entities:  

Keywords:  circular RNA 0004913; clinicopathological characteristics; hepatocellular carcinoma; overall survival; prognostic factor

Mesh:

Substances:

Year:  2021        PMID: 34018640      PMCID: PMC8183933          DOI: 10.1002/jcla.23785

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

1.  Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271.

Authors:  Hai-Feng Liang; Xing-Zeng Zhang; Bao-Guo Liu; Guo-Tao Jia; Wen-Lei Li
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

2.  Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis.

Authors:  Shuwei He; Jianzeng Yang; Shitao Jiang; Yuan Li; Xingmin Han
Journal:  Cancer Cell Int       Date:  2020-08-25       Impact factor: 5.722

Review 3.  Circular RNA in cardiovascular disease.

Authors:  M-Ashraf Altesha; Tiffany Ni; Afaan Khan; Kexiang Liu; Xiufen Zheng
Journal:  J Cell Physiol       Date:  2018-10-20       Impact factor: 6.384

Review 4.  Circular RNA and Alzheimer's Disease.

Authors:  Rumana Akhter
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

5.  ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.

Authors:  Zhicheng Yao; Jingyan Luo; Kunpeng Hu; Jizong Lin; He Huang; Qiangliang Wang; Peng Zhang; Zhiyong Xiong; Chonghua He; Zejian Huang; Bo Liu; Yang Yang
Journal:  Mol Oncol       Date:  2017-03-17       Impact factor: 6.603

6.  Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis.

Authors:  Ivano Legnini; Gaia Di Timoteo; Francesca Rossi; Mariangela Morlando; Francesca Briganti; Olga Sthandier; Alessandro Fatica; Tiziana Santini; Adrian Andronache; Mark Wade; Pietro Laneve; Nikolaus Rajewsky; Irene Bozzoni
Journal:  Mol Cell       Date:  2017-03-23       Impact factor: 17.970

Review 7.  Emerging roles of circRNA in formation and progression of cancer.

Authors:  Yuting Yin; Jiali Long; Qinglian He; Yuling Li; Yanqiu Liao; Peishan He; Wei Zhu
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

8.  Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.

Authors:  Xiao-Yong Huang; Peng-Fei Zhang; Chuan-Yuan Wei; Rui Peng; Jia-Cheng Lu; Chao Gao; Jia-Bing Cai; Xuan Yang; Jia Fan; Ai-Wu Ke; Jian Zhou; Guo-Ming Shi
Journal:  Mol Cancer       Date:  2020-05-19       Impact factor: 27.401

9.  Identification and integrated analysis of hepatocellular carcinoma-related circular RNA signature.

Authors:  Feiran Wang; Xiaodong Xu; Nannan Zhang; Zhong Chen
Journal:  Ann Transl Med       Date:  2020-03

10.  Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression.

Authors:  Shouhua Wang; Yongjie Zhang; Qiang Cai; Mingzhe Ma; Long Yang Jin; Mingzhe Weng; Di Zhou; Zhaohui Tang; Jian Dong Wang; Zhiwei Quan
Journal:  Mol Cancer       Date:  2019-10-17       Impact factor: 27.401

View more
  3 in total

Review 1.  Circular RNAs in hepatocellular carcinoma: Recent advances.

Authors:  Zhao-Shan Niu; Wen-Hong Wang
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

2.  circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD-L1 through NF-κB pathway.

Authors:  Fan Wu; Guoqiang Sun; Wubin Zheng; Weiwei Tang; Ye Cheng; LiangLiang Wu; Xiao Li; Jing Tao; Shijie Ma; Hongyong Cao
Journal:  J Clin Lab Anal       Date:  2021-10-22       Impact factor: 2.352

3.  Hsa_circ_0001806 promotes glycolysis and cell progression in hepatocellular carcinoma through miR-125b/HK2.

Authors:  Xueyi Chen; Pengyun She; Caihua Wang; Lina Shi; Tieying Zhang; Yanfei Wang; Haixia Li; Lu Qian; Man Li
Journal:  J Clin Lab Anal       Date:  2021-10-19       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.